Equity Profile

COLL

Collegium Pharmaceutical, Inc.

Health CarePharmaceuticals$872.6M

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Collegium Pharmaceutical, Inc. is a healthcare company focused on developing and commercializing innovative pain management solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and financial health, and investors will be looking for continued growth.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COLL Q2-2026 Earnings Preview

Context

Company Snapshot

Collegium Pharmaceutical, Inc. is a healthcare company focused on developing and commercializing innovative pain management solutions. With a market cap of $1 billion, it plays a significant role in the pharmaceuticals sector, particularly in addressing the growing need for effective pain relief options.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+18.86%

Avg Stock Reaction

+4.02%

Last Quarter Recap

In Q1-2026, Collegium reported an EPS of $1.76, significantly beating expectations by 43.09%. The stock reacted positively, gaining 7.72% the following day.

Management Promises & Guidance

Continued focus on innovative pain management solutions.
Commitment to expanding market reach and product offerings.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations for Collegium's upcoming earnings are cautiously optimistic, given their strong track record of beating EPS estimates.

Bull Case

If Collegium continues its trend of exceeding EPS expectations, it could signal robust demand for its products and lead to further stock appreciation.

Bear Case

Conversely, any signs of slowing revenue growth or failure to meet EPS expectations could raise concerns about the company's future performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to the previous quarter?

Given Collegium's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

What insights can management provide on revenue growth and market expansion plans?

Investors will be looking for clarity on how the company plans to sustain growth in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Collegium's ability to innovate and capture market share in the pain management space, leading to a potential upside surprise.

Supporting Evidence

Collegium has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting the potential for significant surprises.

Management's commitment to expanding product offerings could drive unexpected revenue growth.

Key Risk

If Collegium's revenue growth exceeds expectations, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Collegium can maintain its growth trajectory amid increasing competition in the pain management sector.

Bull Confirmed If

An EPS of $1.80 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.50 would raise concerns about profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±11.94%

Historical Avg

±4.9%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±11.9% while COLL has averaged ±4.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Collegium beats expectations, history suggests a potential stock increase of around 4.02%, confirming strong demand for its products.

In-Line / Cautious

A cautious but in-line report may lead to muted stock movement as investors digest management's commentary.

Miss

If the company misses expectations, the stock could see a decline, with historical patterns indicating a potential drop of around 4.02%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the pain management sector.
2Details on market share growth and competitive positioning.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on future revenue growth and market conditions.
5Responses to any analyst questions regarding potential risks in the current market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Collegium Pharmaceutical, Inc. is a healthcare company focused on developing and commercializing innovative pain management solutions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and financial health, and investors will be looking for continued growth.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

COLL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+18.86%

Avg Stock Reaction

+4.02%

Last Quarter Recap

In Q1-2026, Collegium reported an EPS of $1.76, significantly beating expectations by 43.09%. The stock reacted positively, gaining 7.72% the following day.

Management Promises & Guidance

Continued focus on innovative pain management solutions.
Commitment to expanding market reach and product offerings.
Plans to enhance operational efficiency.

Expectations

Wall Street Expectations

Overall, expectations for Collegium's upcoming earnings are cautiously optimistic, given their strong track record of beating EPS estimates.

Bull Case

If Collegium continues its trend of exceeding EPS expectations, it could signal robust demand for its products and lead to further stock appreciation.

Bear Case

Conversely, any signs of slowing revenue growth or failure to meet EPS expectations could raise concerns about the company's future performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to the previous quarter?

Given Collegium's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing profitability.

What insights can management provide on revenue growth and market expansion plans?

Investors will be looking for clarity on how the company plans to sustain growth in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Collegium's ability to innovate and capture market share in the pain management space, leading to a potential upside surprise.

Supporting Evidence

Collegium has consistently beaten EPS estimates, indicating strong operational performance.

The options market is pricing a larger move than historical averages, suggesting the potential for significant surprises.

Management's commitment to expanding product offerings could drive unexpected revenue growth.

Key Risk

If Collegium's revenue growth exceeds expectations, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Collegium can maintain its growth trajectory amid increasing competition in the pain management sector.

Bull Confirmed If

An EPS of $1.80 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.50 would raise concerns about profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±11.94%

Historical Avg

±4.9%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±11.9% while COLL has averaged ±4.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.8%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Collegium beats expectations, history suggests a potential stock increase of around 4.02%, confirming strong demand for its products.

In-Line / Cautious

A cautious but in-line report may lead to muted stock movement as investors digest management's commentary.

Miss

If the company misses expectations, the stock could see a decline, with historical patterns indicating a potential drop of around 4.02%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the pain management sector.
2Details on market share growth and competitive positioning.
3Insights into operational efficiencies and cost management strategies.
4Management's outlook on future revenue growth and market conditions.
5Responses to any analyst questions regarding potential risks in the current market.